Geopolitical disruptions (West Asia 2.0)
Q2 is experiencing a 2.0 version of the West Asia crisis unfolding, creating significant supply chain and logistics disruptions beyond Q1 challenges.
Laxmi Organic Industries · risk themes across the available quarters.
Bear-case history
Q2 is experiencing a 2.0 version of the West Asia crisis unfolding, creating significant supply chain and logistics disruptions beyond Q1 challenges.
Large typhoon in South China has created bottlenecks for transportation moving into global direction and into India, affecting supply chain in Q2.
Management acknowledged that Essential margins can swing significantly (Q3 FY26 was under pressure, Q1 FY27 at 11-12%) and guidance is for mid-single digit over cycle—making quarterly sustainability uncertain.
Key raw materials like methanol and acetic acid spiked ~200% when base indexed at 100 in March, creating uncertainty for Q2 despite recent moderation in acetic acid.
Management deflected questions on returning to 22-25% specialty EBITDA margins, citing only that H facility ramp and alternative agrochemical product mapping will help pivot in the right direction without committing to specific timelines.
Analyst pressed on why fluorination revenue guidance of ~200 crore by FY27 remains minuscule relative to total revenues despite years of guidance; management acknowledged the fair question but provided limited expansion clarity beyond FY27.
With 90-95% capacity utilization, analyst questioned why margins cannot improve; management clarified it's a function of spreads × volumes, not just volumes, and acknowledged spreads are at bottom of cycle.
Analyst requested detailed breakdown of specialty revenue decline beyond the stated factors; management deferred to offline follow-up, indicating some granularity remains undisclosed.
Despite recent rebound to $360, Chinese New Year could see capacities come back online and pressure prices. Management expects $330-380 range but acknowledged uncertainty post-holiday period.
The Dahej specialty investment is linked to a multi-year contract with one customer who is simultaneously ramping up their downstream facility. Management declined to disclose current volumes citing customer confidentiality.
Q3 specialty EBITDA margins were 12-13%, well below historical 20-25% range. Management avoided confirming Q3 was the trough, stating 'we will have to navigate it quarter on quarter' and only committed to FY28 for meaningful improvement.
When feedstocks decline, specialty product pricing cannot remain insulated despite the 'specialty' classification. This interconnectedness between commodity and specialty pricing was acknowledged as an ongoing headwind.